Herschel S. Weinstein Senior Counsel

New York
T 646.414.6903 | F 973.597.6335



Vice Chair, Life Sciences Group

Herschel Weinstein is Vice Chair of Lowenstein Sandler’s Life Sciences group. Herschel has 30 years of experience both as in-house and outside counsel in the pharmaceutical industry, including in all aspects of pharmaceutical asset acquisitions, licensing, clinical and pre-clinical drug development, and commercialization.

Prior to joining Lowenstein Sandler, Herschel was Senior Vice President, General Counsel and Secretary at Forest Laboratories, a U.S. based specialty pharmaceutical company with more than $4 billion in annual revenues. As General Counsel and in his private practice, Herschel was responsible for significant licensing, collaboration and acquisition transactions, all significant litigation and regulatory proceedings, responses to major proxy challenges, and legal support for all functions of the organization. In addition, Herschel led the response to various governmental and other investigations and participated in the development of a robust health care law and regulation compliance program.

Prior to joining Forest, Herschel was a partner in the New York law firm of Dornbush, Schaeffer, Strongin & Venaglia, where, in addition to his representation of Forest, Herschel provided corporate, M&A and other transactional representation to a wide variety of publicly-held and private enterprises.

Press Mentions

Lowenstein Sandler represented Emisphere Technologies, Inc. in their development and license agreement with Novo Nordisk A/S, a global healthcare company that focuses on the development of products to benefit people with diabetes and other serious chronic conditions. Novo Nordisk A/S will develop and commercialize oral formulations of four classes of investigational molecules targeting major metabolic disorders, specifically diabetes and obesity, using Emisphere's oral Eligen® Technology. Terms of the agreement grant Novo Nordisk the exclusive right to develop potential product candidates in three molecule classes through Emisphere’s licensing, and the non-exclusive right to develop potential product candidates in a fourth molecule class, using the Eligen® Technology. The Lowenstein deal team included Michael J. LernerIrina Ishak and Herschel S. Weinstein. , October 15, 2015
Lowenstein Sandler represented Pernix Therapeutics Holdings Inc. in its acquisition of the Zohydro® ER Franchise from Zogenix Inc. Under terms of the agreement, Pernix, through its wholly-owned subsidiary, Ferrimill Limited, paid Zogenix $70 million in cash, issued to Zogenix 1,682,086 shares of Pernix common stock and deposited an additional $10 million in cash in escrow to fund potential indemnification claims for a period of 12 months following the closing. Pernix also purchased certain Zohydro ER inventory. The Lowenstein deal team is led by Michael Lerner, Herschel Weinstein, and Park Bramhall, and also included Lowell A. Citron, Marc Kurzweil, Brian A. Silikovitz, Christina Iafe, Jack D. Sidorov, Jeffrey M. Shapiro, Hilla Shimshoni, Tara P. D'Orsi, Michael Amalfe, Sarah Saladini and Eugene Cheval. , April 24, 2015
Lowenstein Sandler represented Celimmune LLC, a clinical development-stage immunotherapy company focused on treating and preventing autoimmune diseases, in connection with its licensing of a Phase 2-stage, anti-IL-15 monoclonal antibody (AMG 714) from Amgen (NASDAQ:AMGN). Financial terms of the agreements were not disclosed. Celimmune plans to initiate Phase 2 studies of AMG 714 for the treatment of diet non-responsive celiac disease and refractory celiac disease (RCD). Celiac disease is a chronic hereditary systemic autoimmune and inflammatory disease triggered by gluten consumption. The Lowenstein team included Michael J. Lerner, Herschel Weinstein, Park S. Bramhall, Brian A. Silikovitz and Lesley P. Adamo. , March 2, 2015

Related Areas

Corporate
Life Sciences

Education


Harvard Law School ( J.D. , 1980 )
Brandeis University ( A.B. ) , cum laude

Bar Admissions


New York